Humana Inc. ($HUM) Stock Forecast: Up 5.5% Today

What is Humana Inc.?

Humana Inc. (NYSE: HUM) is a leading healthcare company specializing in health insurance products and services, with a focus on Medicare Advantage plans. The company has been actively working on improving patient access to care and enhancing the accuracy of its provider directories.

Why is Humana Inc. going up?

HUM stock is up 5.5% on Feb 26, 2026 19:36

• The positive partnership between Humana and data automation startup Veda to enhance provider directories has led to a bullish movement in Humana's stock today, aiming to address inaccuracies in provider information and improve patient care access.
• Despite a significant year-to-date stock price decline, analysts suggest that Humana’s current undervaluation may attract investors seeking discounted opportunities.
• Analysts point out three key factors that could drive Humana's potential upside: strong long-term revenue growth, economies of scale, and a strategic focus on Medicare Advantage plans, indicating consistent growth and capital efficiency.
• The upcoming resolution of Medicare Advantage payment rates may influence investor sentiment towards managed-care stocks like Humana, with a final announcement expected by April 6, following the after-hours slip in UnitedHealth (UNH) stock.

HUM Price Chart

HUM Technical Analysis

HUM News

ViVE 2024: Humana taps data automation startup Veda to polish up provider directories

Humana has partnered with data automation company Veda to enhance the accuracy of its provider directories, aiming to improve patient access to care and reduce administrative burdens. The collaboration leverages Veda's AI platform to analyze, verify, and standardize Humana's provider data, cutting down turnaround times significantly. This initiative addresses the persistent issue of inaccurate provider information, which has been highlighted by various studies and regulatory requirements like the No Surprises Act.

https://www.fiercehealthcare.com/payers/vive-2024-humana-taps-data-automation-startup-veda-polish-provider-directories

Has The Humana (HUM) Share Slump Opened Up A Valuation Opportunity Now

Humana's stock has experienced a significant decline, falling 33.4% year-to-date, prompting questions about its current valuation. Simply Wall St's analysis, utilizing a Discounted Cash Flow model and Price-to-Earnings ratio, suggests that Humana is currently undervalued by 82.6% and undervalued based on its P/E ratio compared to a proprietary Fair Ratio. The article also presents "Narratives" for Humana, including bull and bear cases, to help investors understand contributing factors to its valuation.

https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/has-the-humana-hum-share-slump-opened-up-a-valuation-opportu

FY2028 Earnings Estimate for Humana Issued By Zacks Research

Zacks Research has issued an FY2028 earnings per share (EPS) estimate of $18.36 for Humana Inc. (NYSE:HUM), maintaining a "Strong Sell" rating on the stock. This projection comes after Humana reported a quarterly EPS of ($3.96), surpassing consensus estimates, with revenues up 11.3% year-over-year. The company's stock currently holds an average "Hold" rating from analysts with a consensus target price of $225.48.

https://www.marketbeat.com/instant-alerts/fy2028-earnings-estimate-for-humana-issued-by-zacks-research-2026-02-26/

3 Reasons HUM Has Explosive Upside Potential

Humana (NYSE:HUM) stock has dropped significantly by 41.1% in the last six months to $175.98, primarily due to softer quarterly results. Despite this, the article identifies three key reasons for its potential upside: strong long-term revenue growth, significant economies of scale, and stellar ROIC, suggesting it might be a buying opportunity. The company, which derives over 80% of its revenue from federal government contracts and focuses on Medicare Advantage, demonstrates consistent growth, negotiating leverage, and capital efficiency.

https://finviz.com/news/322938/3-reasons-hum-has-explosive-upside-potential

UnitedHealth (UNH) stock slips after hours as Medicare Advantage rate deadline tightens focus

UnitedHealth (UNH) stock fell after hours as the deadline for comments on the 2027 Medicare Advantage payment rates approached, which previously sparked a selloff in managed-care stocks due to a proposed 0.09% increase. The company also announced a quarterly dividend of $2.21 per share and an amendment to a stock option for Stephen Hemsley. Investors are closely watching the resolution of the Medicare Advantage rates, with the final announcement due by April 6.

https://www.bez-kabli.pl/unitedhealth-unh-stock-slips-after-hours-as-medicare-advantage-rate-deadline-tightens-focus/

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Humana Inc. Price History

26.01.2026 - HUM Stock was up 5.5%

• The positive partnership between Humana and data automation startup Veda to enhance provider directories has led to a bullish movement in Humana's stock today, aiming to address inaccuracies in provider information and improve patient care access.
• Despite a significant year-to-date stock price decline, analysts suggest that Humana’s current undervaluation may attract investors seeking discounted opportunities.
• Analysts point out three key factors that could drive Humana's potential upside: strong long-term revenue growth, economies of scale, and a strategic focus on Medicare Advantage plans, indicating consistent growth and capital efficiency.
• The upcoming resolution of Medicare Advantage payment rates may influence investor sentiment towards managed-care stocks like Humana, with a final announcement expected by April 6, following the after-hours slip in UnitedHealth (UNH) stock.

11.01.2026 - HUM Stock was down 7.6%

• Humana's wider fourth-quarter loss was primarily driven by increased medical costs and decreased quality ratings for its Medicare plans. This led to a less optimistic earnings outlook for 2026.
• Despite exceeding revenue forecasts, concerns about lower quality ratings on its Medicare Advantage plans and the potential loss of government bonus payments affected investor confidence, resulting in a bearish movement for Humana's stock.
• The contrast between the strong revenue performance and the negative earnings forecast for 2026 likely influenced the downward trend in Humana's stock, reflecting a more pessimistic market sentiment towards the company.

11.01.2026 - HUM Stock was down 5.7%

• Humana's ambitious growth strategy to become the largest Medicare Advantage insurer by 2026, despite facing challenges such as elevated medical spending and investor concerns, might have raised doubts among investors, leading to the bearish market movement.
• The wider fourth-quarter loss reported by Humana, driven by surging medical costs and downgraded quality ratings for its Medicare plans, likely contributed to the negative investor sentiment and the stock's decline.
• Despite exceeding revenue forecasts and narrowing its loss compared to the previous year, Humana's disappointing 2026 earnings guidance, falling significantly below analyst expectations, could have triggered the bearish market movement as investors reevaluated the company's future prospects.
• The market's reaction to Humana's performance highlights the importance of managing cost pressures, maintaining plan quality, and meeting investor expectations in the highly competitive healthcare insurance industry.

24.01.2026 - HUM Stock was down 5.1%

• Humana's weaker Q4 2025 results and soft 2026 GAAP EPS outlook have led to a bearish market movement as investors digest the short-term earnings pressures and regulatory uncertainties.
• The company's decision to affirm its dividend despite these challenges signals a dedication to shareholder returns and financial stability, albeit in the face of profitability hurdles.
• Analysts and investors are likely reevaluating Humana's position in the healthcare sector, weighing the affirmed dividend against the backdrop of evolving regulatory risks and the company's strategic focus on medical cost control and value-based care.
• The broader market sentiment towards healthcare stocks, regulatory concerns, and the company's ability to navigate policy-driven risks are contributing factors to Humana's bearish movement today.

27.00.2026 - HUM Stock was down 21.2%

• Humana's stock experienced a strong bearish movement today, dropping over 13% in premarket trading.
• The bearish trend was primarily driven by the Trump administration's proposal of a minimal 0.09% increase in Medicare Advantage payment rates for 2027, significantly below expectations.
• This proposal has raised concerns among analysts and investors about potential benefit reductions or plan exits by insurers like Humana, impacting the company's stock performance.
• The market reaction reflects the heavy reliance of Humana on Medicare Advantage plans and the regulatory uncertainty surrounding future payment rates, leading to a significant sell-off of the stock.

27.00.2026 - HUM Stock was down 20.2%

• The bearish movement in HUM stock today could be attributed to the overall negative sentiment in the health insurance sector, as indicated by the declines in industry peers like UnitedHealth (UNH) and CVS Health (CVS).
• UnitedHealth's reported drop in quarterly earnings and projected revenue decline for 2026, along with plans to reduce Medicare Advantage benefits, likely raised concerns about rising medical costs across the sector, impacting companies like Humana.
• The administration's proposal for near-flat Medicare Advantage rates and a House Judiciary antitrust probe into pharmacy practices also added to the negative market sentiment, leading to the bearish movement in HUM stock.
• Despite recent positive analyst upgrades for Elevance Health (ELV), the broader challenges and uncertainties in the health insurance industry seem to have overshadowed any potential positive developments, contributing to the downward trend in Humana's stock price.

27.00.2026 - HUM Stock was down 19.7%

• Humana and other health insurers like UnitedHealth Group saw declines due to the proposal of flat rates for Medicare Advantage in 2027, surprising investors and leading to a negative market sentiment.
• Lowering the price target for CVS Health amidst concerns over Medicare Advantage rates and a House probe into pharmacy-hub practices may have added to the overall bearish sentiment in the healthcare sector.
• The pre-market trading session showed Humana lagging behind, indicating a continuation of the downward trend influenced by the proposed Medicare reimbursement rates.
• The unexpected news of flat reimbursement rates and the broader political and legal landscape facing health insurers like Humana and UnitedHealth Group contributed to the bearish movement in the stock market today.

27.00.2026 - HUM Stock was down 19.2%

• Humana's share value dropped by more than 20% as a result of the latest proposal by the Trump administration to keep Medicare Advantage payment rates almost stagnant for 2027, a stark contrast to the anticipated 4-6% increase.
• This unforeseen regulatory adjustment not only had repercussions for Humana but also led to a widespread sell-off in the health insurance sector, affecting major players like UnitedHealth Group and CVS Health. This reaction signaled apprehensions regarding narrower profit margins and regulatory ambiguity.
• Despite Humana's strong financial position marked by substantial revenue growth and favorable valuation metrics, the market strongly responded to the regulatory change, introducing substantial uncertainty regarding the company's future earnings.
• The overall market sentiment towards health insurers dependent on Medicare Advantage schemes took a negative turn, resulting in a significant drop in Humana's stock price and underlining the sector's susceptibility to regulatory modifications and governmental policies.

28.00.2026 - HUM Stock was down 9.2%

• Humana's stock experienced a significant 21.13% decline following the Centers for Medicare & Medicaid Services' unexpected announcement of a minimal 0.09% increase in Medicare Advantage payments for 2027.
• The lower-than-anticipated funding raised concerns about profit margins not only for Humana but also for other industry players like CVS Health and UnitedHealth Group.
• The soft outlook for fiscal year 2026, coupled with concerns over proposed payment rates and declining memberships in Medicare Advantage and Medicaid, contributed to investor unease and the bearish movement in Humana's stock.
• As Humana navigates these regulatory challenges and adjusts its cost structures, investors are eagerly awaiting the company's upcoming conference call to gain insights into its earnings performance and short-term outlook amidst the evolving healthcare landscape.

28.00.2026 - HUM Stock was down 7.0%

• Humana Inc. saw a notable decline in its stock price today due to concerns about its Medicare Advantage and Medicaid memberships, compounded by the risk of losing a key contract with The Queen’s Health Systems.
• The company's stock was further affected by the negative sentiment prevailing in the healthcare sector following the announcement of stable funding for Medicare Advantage in 2027 by the Centers for Medicare and Medicaid Services, impacting several insurers like Humana.
• Investor confidence in Humana may have been weakened by regulatory pressures, decreasing reimbursements, and potential care disruptions highlighted by the contract dispute with The Queen’s Health Systems.
• The market movement possibly reflects the uncertainty surrounding Humana's future prospects as investors await updates on its financial performance and strategic plans in a changing healthcare environment.

28.00.2026 - HUM Stock was down 5.7%

• Current concerns about Humana losing a significant contract with Queen’s Health Systems are contributing to the bearish movement in its stock today, potentially impacting 11,000 Medicare Advantage patients and creating uncertainty about its future revenue streams.
• The overall decline in the healthcare sector, influenced by the Centers for Medicare and Medicaid Services' proposed minimal increase in Medicare Advantage payments for 2027, is putting additional pressure on Humana's stock price.
• Despite being considered undervalued by some analysts, the negative investor sentiment towards Humana is influenced by uncertainties related to its contractual disputes and market conditions.
• Michael Burry's recent investment in Molina Healthcare during the insurer's turmoil underscores a changing landscape in the healthcare industry. Companies like Molina, focusing on Medicaid, may offer more stability compared to Medicare-focused insurers like Humana.

10.01.2026 - HUM Stock was down 5.2%

• Humana stock reached a 52-week low at $185.98, marking a significant -27.98% decline over the last year attributed to industry-wide pressures and internal challenges.
• Guggenheim has maintained a Buy rating on Humana stock ahead of its 4Q25 earnings release, citing uncertainties related to guidance, growth in Medicare Advantage enrollment, and profitability.
• The introduction of Agent Assist, an artificial intelligence tool developed by Humana in collaboration with Google Cloud, is expected to improve customer service effectiveness gradually, prompting investors to consider long-term advantages over short-term gains.
• Despite obstacles and varying analyst opinions, the upcoming Q4 2025 earnings report of Humana, coupled with apprehensions regarding policy changes and Medicare Advantage payment rates, are influencing investor sentiment and contributing to the recent market downturn.